Literature DB >> 10900156

Tumor infiltrating lymphocytes in melanoma comprise high numbers of T-cell clonotypes that are lost during in vitro culture.

P thor Straten1, A F Kirkin, E Siim, K Dahlström, K T Drzewiecki, T Seremet, J Zeuthen, J C Becker, P Guldberg.   

Abstract

Melanoma is generally accepted as being an antigenic tumor capable of eliciting T-cell responses that, however, in most cases are inadequate to control tumor growth. Tumor-infiltrating lymphocytes (TIL) in melanoma lesions comprise clonotypic T cells, indicating the in situ recognition of melanoma-associated peptide epitopes. Cultured TIL have been studied in order to unveil characteristics of TIL and the interactions of TIL and melanoma cells. Whether in vitro cultured TIL mirrors the in situ situation has, however, been questioned. In the present study we have taken advantage of T-cell receptor clonotype mapping methodology to conduct a full and detailed analysis of the T-cell clonotypes in melanoma lesions and in corresponding lines of TIL established in vitro. All melanoma lesions and the corresponding TIL cultures comprised high numbers of T-cell clonotypes, typically in the range of 40 to more than 60. The subsequent comparison of T-cell clonotypes present in the original lesions and in the corresponding T-cell lines established in vitro demonstrated that a very limited number of the T-cell clonotypes established in vitro are identical to the T-cell clonotypes expanded in situ. These results demonstrate that in situ T-cell clonotypes in melanoma are not readily expanded in vitro and that the majority of T-cell clonotypes present in cultured TIL are not present in situ. Copyright 2000 Academic Press.

Entities:  

Mesh:

Year:  2000        PMID: 10900156     DOI: 10.1006/clim.2000.4890

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  6 in total

1.  Single-cell T-cell receptor-β analysis of HLA-A*2402-restricted CMV- pp65-specific cytotoxic T-cells in allogeneic hematopoietic SCT.

Authors:  H Nakasone; Y Tanaka; R Yamazaki; K Terasako; M Sato; K Sakamoto; R Yamasaki; H Wada; Y Ishihara; K Kawamura; T Machishima; M Ashizawa; S-I Kimura; M Kikuchi; A Tanihara; J Kanda; S Kako; J Nishida; Y Kanda
Journal:  Bone Marrow Transplant       Date:  2013-08-12       Impact factor: 5.483

2.  Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application.

Authors:  Niels Junker; Per Thor Straten; Mads Hald Andersen; Inge Marie Svane
Journal:  J Skin Cancer       Date:  2011-06-18

3.  Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.

Authors:  Angela Pizzolla; Simon Paul Keam; Ismael A Vergara; Franco Caramia; Niko Thio; Minyu Wang; Nikolce Kocovski; Daniela Tantalo; Jafar Jabbari; George Au-Yeung; Shahneen Sandhu; David E Gyorki; Alison Weppler; Maurizio Perdicchio; Grant A McArthur; Anthony T Papenfuss; Paul Joseph Neeson
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469

4.  T-cell clonotypes in cancer.

Authors:  Per Thor Straten; David Schrama; Mads Hald Andersen; Jürgen C Becker
Journal:  J Transl Med       Date:  2004-04-08       Impact factor: 5.531

5.  Effector CD4 and CD8 T cells and their role in the tumor microenvironment.

Authors:  Sine Hadrup; Marco Donia; Per Thor Straten
Journal:  Cancer Microenviron       Date:  2012-12-16

6.  Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes.

Authors:  Simone P Sittig; Tania Køllgaard; Kirsten Grønbæk; Manja Idorn; Jörg Hennenlotter; Arnulf Stenzl; Cécile Gouttefangeas; Per Thor Straten
Journal:  Oncoimmunology       Date:  2013-09-26       Impact factor: 8.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.